Tag: Biotech and Pharmaceuticals
-
UniQure to seek FDA approval for Huntington’s disease gene therapy after previous clash with agency
The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.
-
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
-
Centene to offer buyouts to some employees as health insurer cuts costs
The health insurer Centene did not indicate to how many employees were offered buyouts or how much it is aiming to reduce its workforce.
-
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
-
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
-
Food supply ‘not at risk’ after new Texas screwworm cases, USDA secretary says
The U.S. will lean on the same playbook it did starting in the late 1950s, part of which involves releasing sterile insects to suppress the pest’s population.
-
Weight loss drug maker sinks 25% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
-
As the largest World Cup ever kicks off, health officials are focused on more than Ebola
Officials are more concerned about highly contagious diseases like measles and respiratory viruses, which can spread quickly through large, fast-moving crowds.
-
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma’s race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
-
Eli Lilly’s top dealmaker says don’t be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly’s new top dealmaker explains how the company changed its approach to M&A now that it’s the most valuable pharmaceutical company in the world.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news china cup Donald J. Trump Donald Trump economy European Union fast football France germany Heatwave Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United Kingdom United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
